GLP-1 Maintenance Dosing: staying off without rebounding

You lost the weight. Now what?

This is the part of the GLP-1 conversation that gets the least airtime and causes the most anxiety. The trial data on stopping these medications is not gentle: when patients come off semaglutide or tirzepatide without a plan, the majority of the weight comes back within a year. But "stay on forever at the full dose" isn't the only alternative. Maintenance dosing — a lower, less frequent, or intermittent dose designed to preserve appetite regulation without the full metabolic load — is now the standard conversation in clinic.

Here's how it actually works.

Why weight comes back when you stop — the biology isn't personal

GLP-1 receptor agonists work by mimicking a gut hormone that slows gastric emptying, blunts appetite signaling in the hypothalamus, and improves insulin response. When you stop the drug, that signaling stops. Ghrelin (your hunger hormone) reasserts itself, and the set-point your body defended before treatment tends to reassert itself too.

The STEP 1 extension trial made this concrete: participants who stopped semaglutide 2.4 mg regained roughly two-thirds of their lost weight within a year of discontinuation (Wilding et al., Diabetes, Obesity and Metabolism, 2022). SURMOUNT-4 showed a similar pattern with tirzepatide — patients randomized to placebo after the lead-in regained about 14% of body weight, while those who stayed on the drug lost an additional 5%.

This is not willpower failure. It is pharmacology. Which is exactly why maintenance dosing exists as a middle path.

What "maintenance dose" actually means

There is no single FDA-defined maintenance dose for weight management the way there is for, say, thyroid replacement. In clinical practice, maintenance typically means one of three approaches:

• Lower fixed dose. Staying on a dose below the full titration target — for semaglutide, that often looks like continuing at a sub-maximal weekly dose rather than 2.4 mg; for tirzepatide, holding at a lower rung of the titration ladder (5, 7.5, or 10 mg) instead of climbing to 15.
• Extended interval dosing. Same dose, but every 10–14 days instead of every 7. Used off-label and clinician-directed; the evidence base is thinner but the pharmacokinetics (semaglutide has a ~7-day half-life) make it plausible.
• Seasonal or cyclical use. Off for a stretch, back on if weight creeps up past a pre-defined threshold (commonly 5% regain).

All three are legitimate. Which one fits depends on how your appetite behaves off the drug, your metabolic markers, and how much of the loss you want to defend.

The taper, step by step

Coming down from a full therapeutic dose to a maintenance dose is not a switch flip. A reasonable taper looks like this:

1. Confirm you're at goal and stable for 4–8 weeks. Weight bouncing ±2 lb around a stable mean is what you want to see before changing anything. 2. Drop one titration rung. For tirzepatide, that might mean 15 → 10 mg, or 12.5 → 7.5 mg. For semaglutide, 2.4 → 1.7 mg. 3. Hold for 8–12 weeks and reassess. Watch weight, waist circumference, and — importantly — appetite. If hunger comes back hard and food noise returns within two weeks, you dropped too fast. 4. Repeat if stable. Some patients maintain on the lowest available dose. Others stabilize two rungs down. A small subset can come off entirely. 5. Have a re-entry rule written down. "If I regain more than 5% of my maintenance weight, I go back up one rung" is a boring sentence that saves a lot of regret.

The patients who keep the weight off are almost always the ones who planned the taper before they needed it — not after the scale started moving.

{callout: The one thing to remember} Maintenance dosing isn't a failure to "finish" treatment — obesity is a chronic condition, and the medication is doing chronic work. The goal is the lowest effective dose that holds your loss, not zero at any cost.

What to monitor during maintenance

The labs worth having on hand during a taper aren't exotic. If you choose to run bloodwork, the markers that actually inform maintenance decisions are:

• Fasting glucose and HbA1c — to confirm metabolic gains are holding.
• Fasting insulin and HOMA-IR — a more sensitive early signal than A1c that insulin resistance is drifting back.
• Lipid panel with ApoB — LDL and triglycerides often improve on GLP-1s; watch for regression.
• ALT/AST — fatty liver improvement is a real GLP-1 benefit worth tracking.
• hs-CRP — inflammation typically drops with weight loss; a rising number can precede a rising scale.

A sensible cadence is baseline at goal weight, then at 3 and 6 months into maintenance. If numbers hold, annual is fine. If they drift, that's your signal to reassess the dose before the scale forces the issue.

The behavioral scaffolding that decides the outcome

The medication does the hardest part — it quiets the appetite signal. But maintenance is where the habits you built during loss either carry you or don't. The patients who do best share a short list of behaviors:

• Protein floor of ~1.6 g/kg of goal body weight. GLP-1 weight loss includes lean mass; protecting muscle protects resting metabolic rate.
• Resistance training 2–3x per week. Non-negotiable for the same reason. ACSM guidance for adults on a caloric deficit or post-deficit maintenance is 2+ sessions weekly hitting all major muscle groups.
• Weekly weigh-in, not daily. Averages, not noise.
• A defined regain threshold. Usually 5% of maintenance weight. Cross it, act. Don't wait for 15%.

None of this is glamorous. All of it works.

When coming off entirely makes sense — and when it doesn't

Some patients do successfully discontinue GLP-1s and hold their loss. The profile tends to look like: modest total weight loss (10–15% rather than 20%+), strong resistance training habit, protein-forward diet locked in, and — often — the underlying driver of weight gain has been addressed (sleep apnea treated, a medication swapped, perimenopause managed, stress load reduced).

If your original driver is still active — chronic sleep deprivation, untreated hypothyroidism, a psychiatric med with weight gain as a side effect, poorly controlled PCOS — the odds of holding a full discontinuation are lower. Maintenance dosing is not a consolation prize in that case. It's the right tool.

Working with a clinician on the plan

Maintenance decisions benefit from a clinician looking at the full picture: your weight trajectory, your appetite behavior off-dose, your labs if you've run them, and your goals. A thorough workup before adjusting a maintenance strategy would typically include the metabolic markers above plus a symptom review. Compounded GLP-1s carry the usual caveat that they aren't FDA-approved as finished products (see our full disclaimer), but the clinical framework for maintenance is the same regardless of formulation.

The honest summary: the drug is doing real work, the biology wants your weight back, and the plan for staying off matters more than the plan for getting off. Build the taper before you need it, watch a small number of markers, and don't confuse a lower dose with a failed treatment. It's the treatment working the way chronic-disease treatment is supposed to work.

Editorial disclosure: This article is for informational purposes only and does not constitute medical advice. All treatments at DirectCare AI are prescribed by US-licensed clinicians based on individual medical evaluation. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Always consult a US-licensed clinician before starting or changing any therapy.